News at XI: moving beyond factor Xa inhibitors

Area of Science:

• Cardiovascular Medicine
• Hematology
• Pharmacology

Background:

• Oral anticoagulants are essential for preventing and treating thrombosis.
• Direct oral anticoagulants (DOACs) like dabigatran, apixaban, edoxaban, and rivaroxaban have largely replaced vitamin K antagonists.
• A new class of anticoagulants targeting factor XIa (FXIa) is emerging.

Purpose of the Study:

• To explore the unmet needs in current oral anticoagulation therapy.
• To highlight factor XIa as a promising target for novel oral anticoagulants.
• To review clinical data and future prospects of FXIa inhibitors.

Main Methods:

• Review of existing literature on anticoagulation therapies.
• Analysis of the coagulation cascade and the role of factor XI.
• Examination of phase 2 clinical trial data for new FXIa inhibitors.
• Overview of ongoing phase 3 trials and parenteral FXI inhibitors.

Main Results:

• Factor XIa inhibition presents a potential for improved safety over current DOACs, as FXI is critical for thrombosis but not essential for hemostasis.
• Early clinical data for oral FXIa inhibitors like asundexian and milvexian are under review.
• Parenteral FXI inhibitors, including antisense oligonucleotides and monoclonal antibodies, are also in development.

Conclusions:

• Factor XIa inhibitors represent a promising advancement in anticoagulation, potentially offering enhanced safety profiles.
• Further research and clinical trials are necessary to establish the efficacy and safety of these novel agents.
• FXIa inhibitors may address significant unmet needs in the management of thrombotic disorders.